S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:NVNO

enVVeno Medical Stock Forecast, Price & News

$9.75
-0.25 (-2.50 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.67
$10.11
50-Day Range
$6.00
$10.59
52-Week Range
$4.99
$17.68
Volume39,339 shs
Average Volume495,455 shs
Market Capitalization$84.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
30 days | 90 days | 365 days | Advanced Chart
Receive NVNO News and Ratings via Email

Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter.


enVVeno Medical logo

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVNO
Employees
19
Year Founded
N/A

Sales & Book Value

Annual Sales
$30,000.00
Book Value
$2.79 per share

Profitability

Net Income
$-9.14 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$84.68 million
Next Earnings Date
11/16/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

1126th out of 1,361 stocks

Surgical & Medical Instruments Industry

109th out of 124 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












enVVeno Medical (NASDAQ:NVNO) Frequently Asked Questions

What stocks does MarketBeat like better than enVVeno Medical?

Wall Street analysts have given enVVeno Medical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but enVVeno Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting enVVeno Medical?

enVVeno Medical saw a increase in short interest in September. As of September 15th, there was short interest totaling 710,900 shares, an increase of 48.3% from the August 31st total of 479,500 shares. Based on an average daily trading volume, of 766,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 8.6% of the shares of the company are sold short.
View enVVeno Medical's Short Interest
.

When is enVVeno Medical's next earnings date?

enVVeno Medical is scheduled to release its next quarterly earnings announcement on Tuesday, November 16th 2021.
View our earnings forecast for enVVeno Medical
.

How were enVVeno Medical's earnings last quarter?

enVVeno Medical Corporation (NASDAQ:NVNO) released its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.06.
View enVVeno Medical's earnings history
.

How has enVVeno Medical's stock been impacted by Coronavirus?

enVVeno Medical's stock was trading at $0.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVNO stock has increased by 1,850.0% and is now trading at $9.75.
View which stocks have been most impacted by COVID-19
.

Who are enVVeno Medical's key executives?

enVVeno Medical's management team includes the following people:

What is enVVeno Medical's stock symbol?

enVVeno Medical trades on the NASDAQ under the ticker symbol "NVNO."

How do I buy shares of enVVeno Medical?

Shares of NVNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is enVVeno Medical's stock price today?

One share of NVNO stock can currently be purchased for approximately $9.75.

How much money does enVVeno Medical make?

enVVeno Medical has a market capitalization of $84.68 million and generates $30,000.00 in revenue each year. The company earns $-9.14 million in net income (profit) each year or ($7.54) on an earnings per share basis.

How many employees does enVVeno Medical have?

enVVeno Medical employs 19 workers across the globe.

What is enVVeno Medical's official website?

The official website for enVVeno Medical is www.hancockjaffe.com.

Where are enVVeno Medical's headquarters?

enVVeno Medical is headquartered at 70 DOPPLER, IRVINE CA, 92618.

How can I contact enVVeno Medical?

enVVeno Medical's mailing address is 70 DOPPLER, IRVINE CA, 92618. The company can be reached via phone at (949) 261-2900.


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.